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Background. Neuronal hyper-excitability characterizes the early stages of Alzheimer’s disease (AD). In animals, early
misfolded tau and amyloid-beta (Aβ) protein accumulation, both central to AD neuropathology, promote cortical excitability
and neuronal network dysfunction. In healthy humans, misfolded tau and Aβ aggregates are first detected, respectively, in
the brainstem and frontomedial and temporobasal cortices, decades prior to the onset of AD cognitive symptoms.
Whether cortical excitability is related to early brainstem tau, and its associated neuroinflammation, and cortical Aβ
aggregations remains unknown.
Methods. We probed frontal cortex excitability, using transcranial magnetic stimulation combined with
electroencephalography, in a sample of 64 healthy late middle-aged individuals (50-69 y; 45 women). We assessed
whole-brain [18F]THK5351 positron emission tomography (PET) uptake as a proxy measure of tau/neuroinflammation,
and whole-brain Aβ burden with [18F]Flutemetamol or [18F]Florbetapir radiotracers.
Results. We find that higher [18F]THK5351 uptake in a brainstem monoaminergic compartment is associated with
increased cortical excitability (r = .29, p = .02). By contrast, [18F]THK5351 PET signal in the hippocampal formation,
although strongly correlated with brainstem signal in whole-brain voxel-based quantification analyses (pFWE-corrected <
.001), was not significantly associated with cortical excitability (r = .14, p = […]
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Background. Neuronal hyper-excitability characterizes the early stages of Alzheimer’s disease 
(AD). In animals, early misfolded tau and amyloid-beta (Aβ) protein accumulation, both central 
to AD neuropathology, promote cortical excitability and neuronal network dysfunction. In 
healthy humans, misfolded tau and Aβ aggregates are first detected, respectively, in the 
brainstem and frontomedial and temporobasal cortices, decades prior to the onset of AD 
cognitive symptoms. Whether cortical excitability is related to early brainstem tau, and its 
associated neuroinflammation, and cortical Aβ aggregations remains unknown.  
Methods. We probed frontal cortex excitability, using transcranial magnetic stimulation 
combined with electroencephalography, in a sample of 64 healthy late middle-aged individuals 
(50-69 y; 45 women). We assessed whole-brain [18F]THK5351 positron emission tomography 
(PET) uptake as a proxy measure of tau/neuroinflammation, and whole-brain Aβ burden with  
[18F]Flutemetamol or [18F]Florbetapir radiotracers.  
Results. We find that higher [18F]THK5351 uptake in a brainstem monoaminergic compartment 
is associated with increased cortical excitability (r = .29, p = .02). By contrast, [18F]THK5351 
PET signal  in the hippocampal formation, although strongly correlated with brainstem signal 
in whole-brain voxel-based quantification analyses (pFWE-corrected < .001), was not significantly 
associated with cortical excitability (r = .14, p = .25). Importantly, no significant association 
was found between early Aβ cortical deposits and cortical excitability (r = -.20, p = .11).  
Conclusion. These findings reveal potential brain substrates for increased cortical excitability 
in preclinical AD and may constitute functional in vivo correlates of early brainstem tau 
accumulation and neuroinflammation in humans. 
Trial registration. EudraCT 2016-001436-35. 
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Alzheimer’s disease (AD) is characterized by a pathogenesis that spreads over decades prior to 
the onset of cognitive symptoms (1). Tau neurofibrillary tangles (NFT) and amyloid-beta (Aβ) 
senile plaques play a central role in this process (2). Post-mortem studies showed that the 
accumulation of misfolded hyperphosphorylated tau protein, which eventually assembles into 
NFT, appears prior to any detectable Aβ lesion (3). By the age of 30, a vast majority of the 
population presents hyperphosphorylated tau aggregates in the brainstem locus coeruleus (LC), 
sometimes concomitantly to other brainstem nuclei such as the dorsal raphe (3–5). Tau 
aggregates and NFT then spread to the entorhinal and hippocampal regions, before following 
its stereotypical outward progression pattern in the cortex, with about half of the post-mortem 
samples showing some NFT by the sixth decade of life (3). By contrast, Aβ senile plaques are 
not found before the fifth decade of life while about 20% of the population present Aβ senile 
plaques between 50 and 60 years (6). Aβ senile plaques also follow a stereotyped progression 
pattern but it is distinct from tau NFT expansion. They are first found in the frontomedial and 
temporobasal areas, before reaching the rest of the neocortex, allocortical brain regions (e.g. 
entorhinal cortex and hippocampus) as well as nuclei from the basal forebrain, and ultimately 
encompass brainstem nuclei and the cerebellum (6, 7).  
Growing evidence supports the idea that AD pathogenesis affects neuronal function 
well before producing neuronal loss and brain atrophy. Increase in neuronal excitability, which 
reflects neuron responsiveness and response selectivity, has been reported to temporarily take 
place before AD symptom onset (8, 9). Motor cortex hyper-excitability was reported in 
prodromal AD (Mild Cognitive Impairment - MCI) (10, 11), while cortical excitability 
decreases markedly in more advanced AD (12). Moreover, acetylcholinesterase inhibitor 
therapy was suggested to restore normal cortical excitability in AD patients (13). This 
temporary increase in cortical excitability has been proposed to represent a compensatory 
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mechanism to face the early brain Aβ or tau deposits (9). Monitoring cortical excitability could 
therefore enhance early/pre-symptomatic risk assessment and diagnosis, and help monitoring 
disease progression.  
The release of both tau and Aβ in the extracellular space are regulated by neuronal 
activity (14, 15). Elevated interstitial and cerebrospinal (CSF) fluid tau and Aβ levels have 
been observed during periods of extended neuronal activity such as sleep deprivation (16, 17). 
In AD animal models, tau pretangles and their surrounding soluble hyperphosphorylated form, 
tau NFTs, Aβ oligomers as well as Aβ senile plaques are known to have a deleterious impact 
on neuronal function (8, 18). In addition, tau presence is associated with inflammatory reaction 
through increased microglial and astrocytic activation (19, 20), which further contribute to 
synaptic dysfunction (21–23). Interestingly though, several studies reported a direct 
relationship between early tau protein accumulation and increased neuronal excitability in 
rodents and drosophila models in distant areas (24–26). Likewise, transgenic AD rodent models 
overexpressing mutant human amyloid precursor protein (APP) revealed that Aβ pathology 
promotes hyperexcitation and hyperactivity of hippocampus and neocortex neurons (27).  
Regional quantification of tau pretangles and soluble hyperphosphorylated forms as 
well as Aβ oligomers remain impossible in vivo in humans, so their direct impact on brain 
function is unknown. In vivo positron emission tomography (PET) imaging of Aβ senile 
plaques has been reliably available in humans for almost 2 decades so their correlates in 
cognitively normal individual and patients are relatively well established (28). In contrast, tau 
NFT in vivo imaging has only been possible over the past 5 years or so (29). In addition, most 
1st and 2nd generation tau PET markers have different degrees of off-binding, including to 
monoamine oxidase-B (MAO-B), which prevents from isolating the specific consequence of 
tau NFT from, for instance, neuroinflammatory processes (30).  
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Here, our main goal was to assess whether, among late middle-aged cognitively normal 
individuals (50 to 69 y), cortical excitability was associated with early tau NFT and 
neuroinflammation burden and with early Aβ senile plaques. We directly measured cortical 
excitability using electroencephalogram (EEG) recordings of brain responses to transcranial 
magnetic stimulation (TMS), which mimics the active brain processing of external stimulation. 
We assessed whole-brain [18F]THK5351 PET uptake as a proxy of tau NFT/neuroinflammation 
burden as well as whole-brain Aβ burden using [18F]Flutemetamol and [18F]Florbetapir PET 
imaging. Based on quantitative magnetic resonance imaging (MRI) data, we then extracted 
[18F]THK5351 and Aβ radiotracer uptake values within their respective first sites of 
accumulation, i.e. in a compartment of the brainstem including monoaminergic neurons for 
[18F]THK5351 uptake, and in the medial prefrontal cortex and inferior temporal lobe for Aβ-
PET (Figure 1, Table 1). We hypothesized that both brainstem [18F]THK5351 and neocortical 













Our analysis first focused on the link between cortical excitability, as assessed with TMS-EEG 
over the frontal cortex (TMS-evoked EEG potential – TEP), and [18F]THK5351 PET signal  in 
the brainstem monoaminergic grey matter (bmGM). We found a significant and positive 
association between TEP slope and bmGM mean [18F]THK5351 standardized uptake value ratio 
(SUVR), both in a simple correlation and after adjusting for TMS-EEG stimulation parameters 
and demographic variables (Pearson’s correlation: r = .29, p = .02; GLMM: F1,57 = 4.76, p = 
.03, R²β* = .08; Figure 2A, Table 2).  
To address the specificity of the highlighted relationship, we then investigated the link 
between cortical excitability and average Aβ centiloid values in stage 1 regions of interest 
(ROI), i.e. in the earliest sites of senile plaques aggregation. We found no significant 
relationship between TEP slope and stage 1 ROI Aβ burden (Pearson’s correlation: r = -.20, p 
= .11; GLMM: F1,57 = 1.41, p = .24; Figure 2B, Table 2). Interestingly, including both bmGM 
[18F]THK5351 SUVR and stage 1 Aβ burden together in the same statistical model, i.e. taking 
into account the variance they respectively explain, still revealed a significant main effect of 
bmGM [18F]THK5351 values (GLMM: F1,56 = 5.78, p = .02, R²β* = .09) but not of stage 1 Aβ 
burden (Table 2). 
Our next step was to further address the regional specificity of the association between 
[18F]THK5351 PET signal and cortical excitability. To do so, we first performed voxel-based 
quantification (VBQ) analyses on standardized [18F]THK5351 SUVR maps to reveal brain 
regions for which [18F]THK5351 radiotracer uptake correlated with bmGM uptake. In line with 
our expectation based on the literature, we found a highly significant correlation with 
[18F]THK5351 values within most of the medial temporal lobe (MTL, pFWE-corrected < .001, 
Figure 3A; Table 3). Interestingly, VBQ outputs in the white matter comprised tracts 
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connecting the brainstem to the MTL, but also widespread projections towards the whole cortex 
(pFWE-corrected < .001; Figure 3B).  
Therefore, we finally extracted mean [18F]THK5351 SUVR over the MTL to test 
whether the positive association between cortical excitability and [18F]THK5351 PET signal  
was dependent on the affected region. Paired t-test analysis showed that mean [18F]THK5351 
SUVR was significantly higher in the MTL compared to the bmGM region (t = 10.14, p < 
.0001; Figure 3C). Yet, we found no significant relationship between cortical excitability and 
mean [18F]THK5351 SUVR in the MTL (Pearson’s correlation: r = .14, p = .25; GLMM: F1,57 
= 1.89, p = .17; Figure 3D, Table 4). Importantly, the correlation value between mean bmGM 
[18F]THK5351 SUVR and cortical excitability was significantly higher than the correlation 















With this cross-sectional study, we show that [18F]THK5351 uptake in a compartment of the 
brainstem including monoaminergic neurons is associated with increased cortical excitability 
in cognitively normal individuals aged 50 to 69 years. We interpret this result with respect to 
tau NFT accumulation and neuroinflammation. By contrast, cortical excitability levels are not 
significantly linked to the presence of Aβ senile plaques measured in their typical earliest 
aggregation sites. We further find that brainstem [18F]THK5351 PET signal co-localizes with 
its uptake in the MTL, in line with human post-mortem studies on tau NFT progression (3). 
However, the association between cortical excitability and [18F]THK5351 uptake in the latter 
region is not significant. Altogether, these findings support that increased cortical excitability 
is specifically related to the presence of tau aggregates and neuroinflammation, potentially in 
a region-specific manner, with the most evident association observed among brainstem 
monoaminergic nuclei.  
[18F]THK5351 is a first generation PET marker of tau NFT that was reported to bind 
substantially to MAO-B associated with neuroinflammation in addition to binding to tau NFT  
(31). Antemortem PET studies of [18F]THK5351 SUVR and postmortem neuropathologic 
studies in progressive supranuclear palsy (32) and AD (29), including ex vivo autoradiography 
with the selective reversible MAO-B inhibitor lazabemide (32), reported that [18F]THK5351 
binding originates to a large extent (~50%) in reactive astrocytes that express increased levels 
of MAO-B (31). This unintended binding is, however, most pronounced over the basal ganglia, 
and is also found, although to a lesser extent, in second generation tau radiotracers (30). 
Neuroinflammation in astrocytes and microglial dysfunction have been proposed to result from 
tau-mediated neurodegeneration of LC neurons, potentially through norepinephrine depletion 
(20, 33, 34). In the rest of the discussion, we therefore interpret brainstem [18F]THK5351 as a 
marker of tau NFT accumulation and of (potentially tau-induced) neuroinflammation, bearing 
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in mind uncertainties and non-specificity of the binding. Future studies should employ 
radiotracers that are more specific to tau protein to further disentangle the respective roles of 
tau NFT, neuroinflammation, and their interaction in the relationship with increased cortical 
excitability. Such radiotracers may be available (35, 36) or are still under development (30, 
37).  
Increased cortical excitability was previously reported in MCI and AD patients, i.e. in 
the presence of cognitive symptoms (10, 11, 13). Our results show that increased cortical 
excitability can also be observed in healthy individuals, potentially during preclinical phases 
of AD, i.e. over the asymptomatic period during which AD-related pathophysiological 
processes evolve and may lead to subsequent symptomatic AD in some individuals. A rationale 
often proposed to account for the increased cortical excitability in MCI and first stages AD 
patients postulates that it represents a compensatory mechanisms to counteract synaptic 
dysfunction and tau NFT accumulation within neuronal networks (9). A computational model 
of neuronal dynamics in AD further reported that the most efficient intervention to counter 
AD-related network dysfunction and enhance its functional survivability was a selective 
increase in excitability of excitatory neurons (38). This compensatory phenomenon may in turn 
favor pathological progression as neuronal hyper-activity increases amyloid-beta and tau 
release (14, 15). Within this scenario, a vicious circle would therefore take place up to a point 
where Aβ, tau and neuroinflammation burden and neurodegeneration would be too important 
to sustain increased excitability (24, 39, 40). This would imply an inverted U-shape relationship 
between cortical excitability and network integrity over AD-related pathophysiological 
processes, with progressive increase in cortical excitability compensating tau-driven synaptic 




The fact that cortical excitability was associated with tau/neuroinflammation PET 
measures in a brainstem region including monoaminergic neurons is compatible with the 
assumption that the association may arise, at least in part, from the LC or from nearby 
monoaminergic nuclei (e.g. raphe) that are part of the ascending reticular activating system. 
Tau NFT/neuroinflammation burden in these nuclei could alter their functioning and their 
impact on distant cortical neurons, e.g. in the prefrontal cortex where we assessed cortical 
excitability. Higher resolution PET and MRI data geared towards isolating brainstem nuclei, 
such as methods based on the neuromelanin-dependent signal of the LC (41), are, however, 
required to truly test this assumption.  
Previous animal studies reported that cortical excitability increased as a function of tau 
burden in the hippocampal region or reported reduced cortical excitability following genetic 
manipulation reducing overall endogenous tau levels (24, 25, 42, 43). However, those studies 
did not specifically assess tau presence in the brainstem, even if the literature would suggest 
that tau accumulation within the LC/brainstem and hippocampal structure should be at least 
partially concomitant (4). Cortical excitability across the different steps of the stereotypical 
outward progression of tau NFTs will have to be monitored to resolve this issue. We 
nevertheless provide original in vivo functional correlates of tau-related PET measures in the 
brainstem in healthy individuals with tau spread limited to its earliest stages.  
The absence of significant link between medial prefrontal cortex excitability and Aβ-
PET marker uptake in the medial prefrontal cortex and inferior temporal lobe is somewhat 
unexpected given the previous links reported in rodents models (27, 44). Yet, Aβ oligomers 
and Aβ senile plaques have also been repeatedly associated with lower synaptic spine density, 
reduced long-term potentiation and increased long-term depression, as well as reduced 
neuronal excitability (45, 46). In addition, hyper-excitability was detected in young AD mutant 
mice suggesting that increased neuronal excitability was independent of Aβ plaque formation 
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(44). Likewise, efficient Aβ immunotherapy in mice failed to restore normal neuronal function 
(44). The relationship between AD pathophysiology and neuronal function is therefore 
complex. Overall, our results suggest that the link between frontal cortical excitability and 
brainstem tau NFT/neuroinflammation burden is more evident than a putative link with medial 
prefrontal and inferior temporal cortex Aβ senile plaques burden.  
Given the cross-sectional nature of our study, we cannot infer about causality, and 
mechanisms underlying our findings remain elusive. In a first scenario, we propose that the 
progressive accumulation of misfolded tau protein in the brainstem, particularly over the LC 
and dorsal raphe nuclei (3), trigger increased cortical excitability as a compensatory mean to 
face tau NFT accumulation and its associated neuroinflammation. Whole-cell patch-clamp 
recordings in a mouse model of progressive tauopathy found that frontal cortical neurons 
exhibit electrophysiological alterations including a more depolarized resting membrane 
potential (47), which would result in increased cortical excitability. In addition, altered 
excitation/inhibition balance and subsequent hyper-excitability may be a consequence of tau 
accumulation through tau-dependent inhibitory interneurons depletion (48). Although these 
observations lend support to our first scenario, they were never focused on brainstem tau 
burden. One cannot exclude therefore a second scenario, where increased cortical excitability, 
which could constitute an endogenous response to environmental factors such as anxiety or 
lack of sleep, would favor tau production, release, and aggregation and neuroinflammation in 
the brainstem.  
Aside from [18F]THK5351 unspecific binding to MAO, our experiment bears additional 
limitations. First, we measured cortical excitability exclusively over the frontal cortex. While 
this area allows for minimally artefacted data and covers the area of earliest Aβ deposit, probing 
cortical excitability over different parts of the cortex may reveal a broader relationship between 
early tau/neuroinflammation and alterations of neuronal function. Another limitation of our 
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study is that it only included healthy individuals with relatively limited tau NFT spread. 
Individuals with more advanced tau pathology, MCI, and early AD patients would have 
provided further characterization of the link between cortical excitability and AD 
pathophysiological progression, and especially tau pathology. Yet, individuals included in our 
study sample were thoroughly screened for their health and cognitive status, reducing the 
probability of biases arising from health conditions or AD-related comorbidities. In addition, 
individuals’ sleep-wake history was carefully controlled prior to TMS-EEG data acquisition, 
and cortical excitability measures were acquired in the morning under strictly controlled 
conditions, after a fixed duration of wakefulness to account for the known changes in cortical 
excitability with prior wakefulness duration and time-of-day (49–52). Furthermore, TMS-EEG 
allows to assess cortical excitability directly and reliably, while bypassing any potential age-
related sensory biases. Finally, we used state-of-the-art brainstem segmentation methods based 
on quantitative multiparametric imaging to automatically and systematically isolate brainstem 
monoaminergic tissue.  
In conclusion, the present results point to brainstem tau NFT and neuroinflammation as 
correlates of the increased excitability observed in the earliest stages of AD neuropathology. 
These findings bring new insights into the interplay between cortical function and the first signs 
of tau aggregation and its associated neuroinflammation in the brainstem. Furthermore, they 
suggest that cortical excitability could constitute a specific biomarker of early misfolded tau 
protein aggregates and neuroinflammation in the brainstem and potentially of increased risk 






Healthy older individuals aged 50-70 years were enrolled in a multi-modal cross-sectional 
study investigating the relationships between AD neuropathology, wake-dependent cortical 
excitability dynamics, and cognitive aging. In that context, we measured cortical excitability 
over the frontal cortex using TMS-EEG, and we performed whole-brain 
tau/neuroinflammation-PET and Aβ-PET imaging. All participants also underwent quantitative 
multiparametric MRI acquisitions for subsequent brainstem segmentation.  
Participants 
One hundred and one healthy older individuals (mean age = 59.4 ± 5.3 years; 68 women) took 
part in this research. Exclusion criteria for the study were: clinical symptoms of cognitive 
impairment (Dementia rating scale < 130 (53); Mini mental state examination < 27); Body 
Mass Index (BMI) ≤ 18 and ≥ 29; recent psychiatric history or severe brain trauma; addiction, 
chronic medication affecting the central nervous system; smoking, excessive alcohol (> 14 
units/week) or caffeine (> 5 cups/day) consumption; shift work in the past 6 months; 
transmeridian travel in the past two months; high levels of anxiety, as measured by the 21-item 
self-rated Beck Anxiety Inventory (BAI ≥ 17) (54); high levels of depression, as assessed by 
the 21-item self-rated Beck Depression Inventory (BDI ≥ 17) (55). Participants with sleep 
apnea (apnea-hypopnea index ≥ 15/hour) were excluded based on an in-lab screening night of 
standard polysomnography.  
A subsample of 65 participants who had data for both tau/neuroinflammation- and Aβ-PET 
assessments was considered for the present paper. One participant was further excluded from 
the study sample because of extreme outlier values on whole-brain [18F]THK5351 PET 
assessment (> 5 standard deviations from the mean). Demographic characteristics of the final 




For 7 days prior to TMS-EEG protocol, participants followed a regular sleep-wake schedule (± 
30 min), in agreement with their preferred bed and wake-up times. Compliance was verified 
using sleep diaries and wrist actigraphy (Actiwatch©, Cambridge Neurotechnology, UK). 
Aside from the fixed sleep-wake schedule, participants were also instructed to abstain from 
unusual physical exercise as well as caffeine and alcohol consumption for the last 3 days of 
fixed sleep-wake schedule. The day before the experiment, participants arrived to the 
laboratory 8 hours before their habitual bedtime and were kept in dim light (< 5 lux) for 6.5 
hours preceding bedtime. Participants then slept a full night of sleep recorded with EEG.  
TMS-EEG assessments were performed on the next day in the context of a 20h protocol 
of wakefulness extension in strictly controlled constant routine conditions, i.e. in-bed semi-
recumbent position (except for scheduled bathroom opportunities), dim light < 5 lux, 
temperature ~19°C, regular isocaloric food intake, no time-of-day information, and sound-
proofed rooms. The protocol schedule was adapted to individual sleep-wake time, and lasted 
up to the theoretical mid-sleep time (e.g. for an individual waking up at ca. 07:00 AM, the 
protocol ended at ca. 03:00 AM in the following night). Cortical excitability over the frontal 
cortex was measured 5 times throughout the protocol. For the present paper, we only 
considered the first assessment of cortical excitability recorded 3 hours after wake-up time (± 
0.21 hours) to avoid any wake-dependent modulation of cortical excitability (51, 52). Other 
considerations related to repeated TMS-EEG sessions are reported elsewhere (51). 
TMS-EEG signal acquisition and processing 
Optimal stimulation parameters (i.e. location, orientation, and intensity) were determined 
during a separate TMS-EEG session carried out prior to the experimental protocol, and allowed 
for EEG recordings free of muscular and magnetic artefacts. As in previous experiments (49, 
50, 52), the target location was in the superior frontal gyrus. For all TMS-EEG recordings, 
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pulses were generated by a Focal Bipulse 8-Coil (Nexstim, Helsinki, Finland). Interstimulus 
intervals were randomized between 1900 and 2200 ms. TMS-evoked responses were recorded 
with a 60-channel TMS-compatible EEG amplifier (Eximia, Helsinki, Finland), equipped with 
a proprietary sample-and-hold circuit which provides TMS artefact-free data from 5 ms post 
stimulation (56). Electrooculogram (EOG) was recorded with two additional bipolar 
electrodes. EEG signal was band-pass filtered between 0.1 and 500 Hz and sampled at 1450 
Hz. Before each recording session, electrodes impedance was set below 5 kΩ. Each TMS-EEG 
session included ~250 trials. Auditory EEG potentials evoked by the TMS clicks and bone 
conductance were minimized by diffusing a continuous white noise through earphones and 
applying a thin foam layer between the EEG cap and the TMS coil. 
TMS-EEG data were pre-processed as previously described (50, 52) in Statistical 
Parametric Mapping 12 (SPM12, http://www.fil.ion.ucl.ac.uk/spm/) implemented in 
MATLAB2013a (The Mathworks Inc., Natick, MA, USA). In brief, TMS-EEG data underwent 
semi-automatic artefacts rejection, low-pass filtering at 80 Hz, downsampling to 1000 Hz, 
high-pass filtering at 1 Hz, splitting into epochs spanning -101 and 300 ms around TMS pulses, 
baseline correcting (from -101 to -1 ms pre-TMS), and robust averaging. Cortical excitability 
was defined as the slope at the inflexion point of the first component (0-35 ms) of the TMS-
evoked EEG potential (TEP) measured on the artefact-free electrode closest to the target 
stimulation location. Median position of the closest artefact-free recording electrode was [X: -
34; Y: -3.7; Z: 85.9, mm, Montreal Neurological Institute (MNI) space].  
Quantitative multi-parametric acquisition and processing 
All MRI acquisitions were performed on a 3-T scanner (MAGNETOM Prisma, Siemens). 
Structural and quantitative maps of T1, T2*, proton density (PD) and magnetization transfer 
(MT) with 1 mm isotropic resolution were computed based on a multi-parameter protocol 
including 3D multi-echo fast low angle shot (FLASH) sequence (57). Three co-localized 3D 
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multi-echo FLASH data sets were acquired with predominantly proton density weighting 
(PDw: TR/FA=23.7 ms/6°), T1 weighting (T1w: TR/FA=18.7 ms/20°), and MT weighting 
(MTw: TR/FA=23.7 ms/6°; excitation preceded by an off-resonance Gaussian MT pulse of 5 
ms duration, 220° nominal flip angle, 2 kHz frequency offset) in a total acquisition time of 
approx. 19 min, with a voxel size of 1 mm³ isotropic. Two calibration sequences were acquired 
to correct for inhomogeneities in the radio frequency transmit field. 
Quantitative multi-parametric maps (MT, PD, R1, R2*) were generated with the hMRI 
toolbox (58) (http://hmri.info) implemented in MATLAB2013a. First, MT and PD maps were 
segmented into grey, white, and CSF tissue class maps using Unified Segmentation (US) within 
SPM12 (59). Whole-brain segmentation outputs were diffeomorphically registered to a study-
specific template, compatible with the MNI space, created using Shoot toolbox in SPM12 (60) 
in order to generate deformation fields that were used to warp MT and PD maps into the Shoot 
common-average space. Brainstem segmentation was then performed using US with brainstem 
sub-regions tissue probability maps that were generated according to previously described 
methods based on a modified multivariate mixture of Gaussians (61). Out of the four brainstem 
tissue classes produced, we considered only tissue class 1 which encompassed monoaminergic 
grey matter, including LC and raphe nuclei. Brainstem monoaminergic grey matter (bmGM) 
tissue was then warped back to individual space, using inverse deformation fields. Finally, 
bmGM tissue was binarized and applied as a mask on coregistered PET [18F]THK5351 for signal 
extraction, as described below.  
PET acquisition and pre-processing 
Tau/neuroinflammation and Aβ PET imaging were performed on an ECAT EXACT+ HR 
scanner (Siemens, Erlangen, Germany), with a 2 mm isotropic resolution. 
Tau/neuroinflammation PET imaging was performed with radiotracer [18F]THK5351 for all 
subjects. Aβ-PET imaging was achieved with radiotracer [18F]Flutemetamol for 61 subjects and 
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with [18F]Florbetapir for 3 subjects.  For all PET imaging, participants received a single dose of 
the respective radiotracer in an antecubital vein (target dose ~185 MBq). For 
tau/neuroinflammation-PET, a 10-minute transmission scan was first acquired, and dynamic 
image acquisitions started immediately after injection, consisting in 32 frames with increasing 
time duration (total time spent in scanner ~100 min.). For Aβ-PET, image acquisitions started 
85 minutes after injection, and 4 frames of 5 minutes were obtained. All PET images were 
reconstructed using filtered back-projection algorithm including corrections for measured 
attenuation, dead time, random events, and scatter using standard software (ECAT 7.1, 
Siemens/CTI, Knoxville, TN, USA). For each individual, an average PET image was created 
using all frames for Aβ-PET, and the 4 frames corresponding to the time window between 40 
and 60 min for tau/neuroinflammation-PET (62). Averaged PET images were manually 
reoriented and automatically coregistered to the structural MT map.  
Standardized uptake value ratio (SUVR) was calculated using the cerebellum grey 
matter as the reference region for tau/neuroinflammation-PET (32), and the whole cerebellum 
for Aβ-PET (63). Given that we used 2 different radiotracers for Aβ-PET imaging, Aβ SUVR 
values were further scaled to centiloid units ((63–65). Subject-space bmGM mask was applied 
on [18F]THK5351 SUVR maps to retrieve mean tau/neuroinflammation burden. A region of 
interest comprising the earliest Aβ accumulation sites (stage 1 ROI) (7) was built based on 
bilateral regions from the automated anatomical labelling 2 (AAL2) atlas (66), including 
superior medial frontal, fusiform, and inferior temporal cortices, and was applied on the 
standardized Aβ maps. 
Mean [18F]THK5351 SUVR was 1.43 ± 0.11 over the whole brain, and 1.97 ± 0.20 in 
the brainstem monoaminergic grey matter. Mean whole-brain Aβ centiloid value was 2.47 ± 
9.92, and -5.31± 8.20 in the stage 1 ROI. The negative centiloid values in these earliest Aβ 
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accumulation sites were expected, as our sample comprises only healthy participants in late 
middle-age who were thoroughly screened for absence of many comorbidity factors. 
 While first generation tau protein radiotracers, including [18F]THK5351, have been 
widely studied and proved to have high affinity and selectivity in vitro (31), criticisms were 
raised about their off-binding to MAO-B in vivo, particularly over the basal ganglia (67). 
However, as investigated in a recent comparative analysis of first and second generation 
radiotracers, this off-target binding may be common to all first generation radiotracers and, to 
a lesser extent, also to second generation radiotracers (30). We therefore consider that 
[18F]THK5351 uptake arises from about equal proportion of binding to both tau NFT and MAO-
B (31), and constitutes a marker of both tau and neuroinflammation burden. 
Tau co-localization analysis 
Spatial processing of PET images for voxel-based quantification (VBQ) analyses was achieved 
with the ‘standard pipeline’ module in hMRI toolbox. Whole-brain [18F]THK5351 SUVR maps 
were diffeomorphically registered to the study-specific template using individual deformation 
fields, warped into the MNI space and tissue-specific smoothing (full width at half-maximum 
of 6 mm isotropic, separately for grey and white matter) was applied. VBQ analyses were 
carried out on these images in SPM12 in order to highlight brain regions which correlate with 
tau/neuroinflammation burden in the bmGM tissue. Statistical modelling consisted in a 
multiple linear regression model including four regressors (i.e. demographic variables of age, 
sex, education, and bmGM mean [18F]THK5351 SUVR). One-tailed t tests were used to identify 
voxels displaying increased [18F]THK5351 SUVR associated with higher values in the bmGM 
compartment. Statistical threshold was set at p < 0.05 after family-wise error (FWE) correction 
for multiple comparisons (pFWE-corrected) voxel-wise for the whole-brain. Grey matter and white 
matter tissue classes were analyzed separately using explicit masks defining voxels belonging 
to each tissue class. These masks were generated using the across-subjects average of smoothed 
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Jacobian-modulated tissue probability maps in MNI space, with a minimum probability 
threshold of 20%, and voxels were assigned to the tissue class for which the probability was 
maximal. For both VBQ analyses, bmGM area was further masked to avoid redundancy.  
Statistics 
Statistical analyses were performed using Pearson’s correlations and Generalized Linear Mixed 
Models (GLMMs) in SAS 9.4 (SAS Institute, Cary, NC, USA). Pearson’s correlations were 
used as an assessment of potential association before computing GLMM which accounted for 
possible biases and covariate influences. Dependent variable distribution was first determined 
using ‘allfitdist’ function (developped by Mike Sheppard) in MATLAB2013a and GLMMs 
were adjusted accordingly. TMS-EEG stimulation parameters of applied electric field and 
distance between hotspot and recording electrode were included as covariates in GLMM 
statistical models with cortical excitability measures as dependent variables. All GLMMs were 
adjusted for demographic variables of age, sex and education. Subject (intercept) was included 
as a random factor. Degrees of freedom were estimated using Kenward-Roger’s correction. 
Statistical significance was set at p < .05. Semi-partial R² (R²β*) values were computed to 
estimate the effect sizes of significant fixed effects and statistical trends in all GLMMs (68). 
Study approval 
This study was approved by the Ethics Committee of the Faculty of Medicine at the University 
of Liège, Belgium. Participants gave their written informed consent prior to inclusion in the 
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Figure 1. Cortical excitability assessment and PET values extraction in early deposition 
sites. (A) Cortical excitability over the frontal cortex was assessed using neuronavigation-
based TMS coupled to EEG. TMS-EEG target area was located in the superior frontal gyrus. 
Darker and brighter yellow areas represent the range of stimulation targets across participants 
projected onto the averaged normalized T1 structural volume and the median TMS-EEG 
stimulation hotspot over the sample, respectively. (B) Butterfly plot of TMS-evoked EEG 
response over the 60 electrodes (-100 ms pre-TMS to 300 ms post-TMS; average of ~250 
trials). Cortical excitability was computed as the slope (µV/ms, dotted line on inset) of the first 
component of the TEP response at the electrode closest to the stimulation hotspot. (C) 
Automatic brainstem segmentation methods were used to extract  [18F]THK5351 SUVR in the 
brainstem monoaminergic grey matter (bmGM; top row). Aβ burden ([18F]Flutemetamol or 
[18F]Florbetapir centiloid units) was extracted in the earliest aggregation sites (7) using bilateral 










Figure 2. Associations between cortical excitability and early [18F]THK5351 PET signal as 
well as Aβ burden. (A) Significant and positive association between cortical excitability 
values and mean [18F]THK5351 standardized uptake value ratio (SUVR) in the brainstem 
monoaminergic grey matter (bmGM; Pearson’s correlation: r = .29, p = .02; GLMM: F1,57 = 
4.76, p = .03, R²β* = 0.08). (B) No significant association between cortical excitability and mean 
[18F]Flutemetamol/[18F]Florbetapir (centiloid units) in a region-of-interest covering the earliest 
Aβ aggregation sites (Pearson’s correlation: r = -.20; p = .11; GLMM: F1,57 = 1.41, p = .24). 
Simple regressions are displayed and full GLMMs outputs are reported in Table 2. Dotted lines 


























Figure 3. [18F]THK5351 regional correlates of brainstem [18F]THK5351 uptake,  and 
association between cortical excitability and mean MTL [18F]THK5351 SUVR. (A) VBQ 
analyses revealed that mean [18F]THK5351 SUVR in the brainstem monoaminergic grey matter 
(bmGM) region was positively correlated to grey matter [18F]THK5351 PET signal within most 
of the medial temporal lobe (MTL, pFWE-corrected < .001). (B) VBQ analyses further showed that 
mean [18F]THK5351 SUVR in the bmGM region was positively associated with [18F]THK5351 
SUVR in the white matter tracts connecting the brainstem to the MTL, but also in widespread 
projections towards the whole cortex (pFWE-corrected < .001). (C) Paired t-test analysis showed 
that mean [18F]THK5351 SUVR in the bmGM was significantly lower than in the MTL (t = 
10.14, p < .0001). (D) Average [18F]THK5351 SUVR in the MTL was, however, not 
significantly associated with cortical excitability values (Pearson’s correlation: r = .14, p = .25; 
GLMM: F1,57 = 1.89, p = .17). Simple regression is displayed and full GLMM outputs are 





Table 1. Sample characteristics (mean ± SD). 
 N = 64 
Sex 45F/19M 
Age (years) 59.7 ± 5.5  
Education (years) 15.3 ± 3.1 
Right-handed (%) 97 
Ethnicity Caucasian 
Dementia Rating Scale 142.3 ± 2 
Body mass index (Kg/m²) 24.5 ± 2.8 
Whole-brain [18F]THK5351 (SUVR) 1.31 ± 0.09 
Brainstem monoaminergic grey matter [18F]THK5351 (SUVR) 1.98 ± 0.20 
Hippocampal/entorhinal cortex [18F]THK5351 (SUVR) 2.11 ± 0.18  
Whole-brain [18F]Flutemetamol/[18F]Florbetapir (Centiloid value) 2.47 ± 9.92 
Stage 1 region-of-interest [18F]Flutemetamol/[18F]Florbetapir (Centiloid value) -5.31± 8.20  
TMS-evoked cortical excitability (µV/ms) 1.09 ± 0.48 
TMS applied electric field (V/m²) 114.7 ± 15 
Recording electrode distance from TMS hotspot (mm) 45.4 ± 10.5 
F = female; M = male; SUVR= standardized uptake value ratio. Stage 1 refers to the earliest 




Table 2. GLMM outputs of the associations between cortical excitability values and mean 
[18F]THK5351 SUVR  in the brainstem monoaminergic grey matter (bmGM, model 1), 
mean Aβ in the stage 1 ROI (model 2), and both considered together (model 3). 
In all models, TEP slope was used as the dependent variable as a measure of cortical 
excitability. R²β* values correspond to semi-partial R² in GLMMs, and are reported for all 
significant associations. 
  
 Model 1  Model 2 Model 3 
Mean bmGM [18F]THK5351 SUVR  
F1,57 = 4.76  
p = 0.03 
R²β* = 0.08 
 
 
F1,56 = 5.78  
p = 0.02 
R²β* = 0.09 
Mean stage 1 Aβ burden  
F1,57 = 1.41  
p = 0.24 
F1,56 = 2.43  
p = 0.12 
Age 
F1,57 = 2.59  
p = 0.11 
F1,58 = 1.62  
p = 0.21 
F1,56 = 1.27  
p = 0.26 
Sex 
F1,57 = 0.02 
p = 0.88 
F1,57 = 0.37  
p = 0.54 
F1,56 = 0.01  
p = 0.94 
Education 
F1,57 = 3.04 
p = 0.09 
F1,57 = 1.38  
p = 0.25 
F1,56 = 2.56  
p = 0.11 
Electric field 
F1,57 = 1.50 
p = 0.23 
F1,57 = 0.74  
p = 0.39 
F1,56 = 1.36  
p = 0.25 
Recording electrode distance 
F1,57 = 3.62 
p = 0.06 
F1,57 = 3.30  
p = 0.07 
F1,56 = 3.35  
p = 0.07 
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Table 3. Statistical outputs of VBQ grey matter analysis seeking for correlation between 
brainstem monoaminergic grey matter region [18F]THK5351 uptake and [18F]THK5351 
SUVR in the rest of the brain grey matter, after adjusting for age, sex, and education.  
 
Voxel size = 2 mm³; Degrees of freedom = [1,59]. % Cluster refers to the proportion of cluster 
voxels that are assigned to the corresponding anatomical localization label. Given the extent of 
the first significant cluster, only the major localization labels are reported. 
  





(cluster level) Localization label 
 
% Cluster 
12743 2 -16 -16 < .001 Left hippocampus 6.27 
   Left thalamus 6.24 
   Right parahippocampus 5.85 
   Right hippocampus 5.75 
   Right thalamus 5.72 
   Right putamen 5.65 
   Left parahippocampus 4.87 
   Left putamen 3.37 
   Right caudate 3.23 
151 2 20 22 < .001 Right anterior cingulum 60.26 
   Left anterior cingulum 39.74 
104 -2 -26 30 < .001 Left posterior cingulum 30.77 
   Right posterior cingulum 16.35 
   Left middle cingulum 15.38 
   Right middle cingulum 13.46 
89 -38 -36 18 < .001 Left Rolandic operculum 40.45 
   Left superior temporal 38.20 
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Table 4. GLMM outputs of the associations between cortical excitability values and mean 
[18F]THK5351 SUVR  in the medial temporal lobe (MTL). 




Mean MTL [18F]THK5351 SUVR 
F1,57 = 1.89  
p = 0.17 
Age 
F1,57 = 3.59  
p = 0.06 
Sex 
F1,57 = 0.19 
p = 0.66 
Education 
F1,57 = 2.53 
p = 0.12 
Electric field 
F1,57 = 0.96 
p = 0.33 
Recording electrode distance 
F1,57 = 3.59 
p = 0.06 
